A randomized double blind parallel group multicenter multinational study to assess glycemic control with rimonabant in comparison with glimepiride over 1 year in overweight/obese type 2 diabetic patients not adequately controlled with metformin

Trial Profile

A randomized double blind parallel group multicenter multinational study to assess glycemic control with rimonabant in comparison with glimepiride over 1 year in overweight/obese type 2 diabetic patients not adequately controlled with metformin

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Rimonabant (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ALLEGRO
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Jun 2009 Sanofi-Synthelabo added as trial sponsor and affiliate as reported by Clinical Trials Registry - India
    • 24 Jun 2009 New source identified and integrated (Clinical Trials Registry - India).
    • 23 Jun 2009 Actual number of patients (508) added, additional trial locations India and Puerto Rico identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top